Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Ideaya submits IND for phase I evaluation of MAT2A inhibitor IDE-397

Jan. 11, 2021

Dana-Farber Cancer Institute patents EGFR allosteric inhibitors

Jan. 11, 2021

CARs with switches

Jan. 11, 2021

Pfizer and CTxT Pty synthesize KAT inhibitors

Jan. 8, 2021

Chinese researchers presents new SERCAs for breast cancer

Jan. 8, 2021

Beijing Reciproca Pharmaceuticals patents new CDK inhibitors

Jan. 8, 2021

New ISR pathway inhibitors presented by Praxis Biotech

Jan. 7, 2021

JS Innopharm (Shanghai) identifies RET and/or VEGFR-2 inhibitors

Jan. 7, 2021

IHMT-TRK-284 shows efficacy in models of TRK kinase fusion or mutant-driven cancers

Jan. 7, 2021

The Vanderbilt University synthesizes new compounds for cancer

Jan. 7, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...